
Nancy E Morden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10510415/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intense Use of Fracture-Associated Drugs Among Medicare Beneficiaries in Long-term Care. Journal of General Internal Medicine, 2021, 36, 1818-1820.	2.6	2
2	Regional Variation in Fracture-Associated Prescription Drug Use and Hip Fractures in Long-Term Care: an Observational Study. Journal of General Internal Medicine, 2021, 36, 3604-3607.	2.6	0
3	A proposed taxonomy for population-level prescription use patterns. Journal of Prescribing Practice, 2021, 3, 22-27.	0.1	Ο
4	Racial Inequality in Prescription Opioid Receipt — Role of Individual Health Systems. New England Journal of Medicine, 2021, 385, 342-351.	27.0	88
5	Trends in Testosterone Prescriptions for Older Men Enrolled in Commercial Insurance and Medicare Advantage. JAMA Network Open, 2021, 4, e2127349.	5.9	3
6	Low-Value Care at the Actionable Level of Individual Health Systems. JAMA Internal Medicine, 2021, 181, 1490.	5.1	28
7	Prevalence and Cost of Care Cascades After Low-Value Preoperative Electrocardiogram for Cataract Surgery in Fee-for-Service Medicare Beneficiaries. JAMA Internal Medicine, 2019, 179, 1211.	5.1	70
8	Association of Receiving Multiple, Concurrent Fracture-Associated Drugs With Hip Fracture Risk. JAMA Network Open, 2019, 2, e1915348.	5.9	19
9	Trends in Testosterone Prescribing for Age-related Hypogonadism in Men With and Without Heart Disease. JAMA Internal Medicine, 2019, 179, 446.	5.1	18
10	Direct oral anticoagulant and antiplatelet combination therapy: Hemorrhagic events in coronary artery stent recipients. Journal of Clinical Neuroscience, 2018, 50, 24-29.	1.5	3
11	Payer Type and Lowâ€Value Care: Comparing Choosing Wisely Services across Commercial and Medicare Populations. Health Services Research, 2018, 53, 730-746.	2.0	38
12	Overuse and insurance plan type in a privately insured population. American Journal of Managed Care, 2018, 24, 140-146.	1.1	3
13	For Selected Services, Blacks And Hispanics More Likely To Receive Low-Value Care Than Whites. Health Affairs, 2017, 36, 1065-1069.	5.2	55
14	Atrial Fibrillation and Stent Selection (Bare Metal vs Drug Eluting) (from Medicare Claims). American Journal of Cardiology, 2017, 120, 1557-1561.	1.6	1
15	State Regulations and Opioid Use among Disabled Adults. New England Journal of Medicine, 2016, 375, 1396-1397.	27.0	2
16	State Legal Restrictions and Prescription-Opioid Use among Disabled Adults. New England Journal of Medicine, 2016, 375, 44-53.	27.0	208
17	Prescription Use among Children with Autism Spectrum Disorders in Northern New England: Intensity and Small Area Variation. Journal of Pediatrics, 2016, 169, 277-283.e2.	1.8	18
18	Diabetes Pharmacotherapies and Bladder Cancer: A Medicare Epidemiologic Study. Diabetes Therapy, 2016, 7, 61-73.	2.5	16

NANCY E MORDEN

#	Article	IF	CITATIONS
19	Role of Pharmacy Services in Accountable Care Organizations. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 338-344.	0.9	17
20	Choosing Wisely: Prevalence and Correlates of Low-Value Health Care Services in the United States. Journal of General Internal Medicine, 2015, 30, 221-228.	2.6	206
21	Use of non-indicated cardiac testing in low-risk patients: Choosing Wisely. BMJ Quality and Safety, 2015, 24, 149-153.	3.7	36
22	Choosing Wisely — The Politics and Economics of Labeling Low-Value Services. New England Journal of Medicine, 2014, 370, 589-592.	27.0	227
23	Response Letter to Herbert L. Muncie, Jr Journal of the American Geriatrics Society, 2014, 62, 998-999.	2.6	0
24	Prescription Opioid Use Among Disabled Medicare Beneficiaries. Medical Care, 2014, 52, 852-859.	2.4	122
25	Accountable Prescribing. New England Journal of Medicine, 2013, 369, 299-302.	27.0	7
26	Quality of Osteoporosis Care of Older Medicare Recipients with Fragility Fractures: 2006 to 2010. Journal of the American Geriatrics Society, 2013, 61, 1855-1862.	2.6	35
27	Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D Patients With Diabetes. Annals of Internal Medicine, 2013, 159, 105-14.	3.9	30
28	End-Of-Life Care For Medicare Beneficiaries With Cancer Is Highly Intensive Overall And Varies Widely. Health Affairs, 2012, 31, 786-796.	5.2	198
29	Sources of Regional Variation in Medicare Part D Drug Spending. New England Journal of Medicine, 2012, 366, 530-538.	27.0	68
30	Association of Age, Gender, and Race with Intensity of End-of-Life Care for Medicare Beneficiaries with Cancer. Journal of Palliative Medicine, 2012, 15, 548-554.	1.1	123
31	Impact of Payment Reform on Chemotherapy at the End of Life. Journal of Oncology Practice, 2012, 8, e6s-e13s.	2.5	32
32	Eight-year trends of cardiometabolic morbidity and mortality in patients with schizophrenia. General Hospital Psychiatry, 2012, 34, 368-379.	2.4	36
33	Impact of payment reform on chemotherapy at the end of life. American Journal of Managed Care, 2012, 18, e200-8.	1.1	6
34	Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer. Diabetes Care, 2011, 34, 1965-1971.	8.6	86
35	Quality of Care for Cardiometabolic Disease. Medical Care, 2010, 48, 72-78.	2.4	10
36	Health Care for Patients with Serious Mental Illness: Family Medicine's Role. Journal of the American Board of Family Medicine, 2009, 22, 187-195.	1.5	71

NANCY E MORDEN

#	Article	IF	CITATIONS
37	Excess heart-disease-related mortality in a national study of patients with mental disorders: identifying modifiable risk factors. General Hospital Psychiatry, 2009, 31, 555-563.	2.4	158
38	Medicaid Prior Authorization and Controlled-Release Oxycodone. Medical Care, 2008, 46, 573-580.	2.4	34
39	Trends and Geographic Variation of Opiate Medication Use in State Medicaid Fee-For-Service Programs, 1996 to 2002. Medical Care, 2006, 44, 1005-1010.	2.4	137
40	States' Control Of Prescription Drug Spending: A Heterogeneous Approach. Health Affairs, 2005, 24, 1032-1038.	5.2	16